Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from NurExone Biologic ( (TSE:NRX) ) is now available.
NurExone Biologic Inc. announced its second quarter 2025 financial results, highlighting a C$2.3 million raised through a private placement to support working capital and clinical development activities. The company is progressing towards initiating a Phase 1/2a trial for ExoPTEN in 2026 and enhancing its manufacturing capabilities through a tech transfer to its U.S. subsidiary, Exo-Top Inc. Additionally, NurExone’s acceptance into the ARMI HealthTech Hub Accelerator is set to bolster its U.S. growth and manufacturing strategy.
The most recent analyst rating on (TSE:NRX) stock is a Buy with a C$2.61 price target. To see the full list of analyst forecasts on NurExone Biologic stock, see the TSE:NRX Stock Forecast page.
More about NurExone Biologic
NurExone Biologic Inc. is a preclinical-stage biotechnology company specializing in exosome-based therapies for central nervous system injuries. The company focuses on developing innovative treatments and advancing its research and development efforts in the biotechnology industry.
Average Trading Volume: 42,349
Technical Sentiment Signal: Buy
Current Market Cap: C$50.93M
See more data about NRX stock on TipRanks’ Stock Analysis page.